with more days of asthma symptoms. Fig 1 presents a binary version of these results. Further details are provided in the Results section in this article's Online Repository.
To our knowledge, this is the first study to evaluate the prevalence and concentrations of environmental S aureus and SEs in a multicenter population of inner-city adolescents with asthma. More than 80% of the adolescents we evaluated in the multicenter ACE study were exposed to a detectable number of S aureus genes in home dust in this population. Exposures to detectable numbers of SE genes in home dust also were common in this study, ranging from 36% (SEB and SEC) to more than 60% (SEA). Although there is a growing literature on detection of S aureus, particularly methicillin-resistant Staphylococcus aureus, in the home environment related to infection outcomes, 2 few prior studies have evaluated S aureus in the home environment in the context of asthma, 8, 9 and none have done so in this population. Given that staphylococcal exposures can induce inflammation through both IgE-dependent and independent mechanisms, this finding can have important implications for asthma among inner-city adolescents. This study's findings support the hypothesis that environmental SE exposures have the potential to elicit asthma symptoms, although results were not uniform across outcomes. Environmental exposures to SEA were associated consistently with multiple symptom outcomes among asthmatic patients without eczema, which was the opposite of our hypothesis that asthmatic patients with eczema would have worse disease. A growing literature supports the biological plausibility of inflammatory responses and illness from environmental staphylococcal exposures. Limitations of the study were that the cross-sectional assessment precluded demonstration of causal relationships and that gene detection was used as a proxy for bacterial and protein exposures. The Discussion section in this article's Online Repository at www.jacionline.org provides additional discussion regarding history of eczema, biological plausibility, and study limitations.
Given the novelty of these findings, it is important to pursue future research to replicate these results in other populations and to conduct prospective longitudinal studies to evaluate whether environmental exposures to SEs can be causally associated with asthma morbidity. Furthermore, the finding that SEA home environmental exposures were associated with worse disease among participants who did not report a history of eczema suggests that host susceptibility might be important to this relationship. Future work should focus on elucidating host susceptibility factors and understanding the potential mechanism or mechanisms by which SE could be associated with asthma symptoms.
We thank the Inner-City Asthma Consortium for sharing of home dust extracts and data. We also thank Dr John Groopman and his research group, particularly Pat Egner, for their support. 4, 5 The clinical presentation was broadly reflected in our cohort (see Table E1 in this article's Online Repository at www.jacionline.org).
An appreciation of the true burden and nature of liver pathology in patients with XHIM has been limited; hence, we present a detailed characterization of liver pathology in a sizeable cohort of patients with XHIM from several United Kingdom (UK) centers.
All UK centers submitting XHIM data to the UK Primary Immunodeficiency Network were asked to complete a standardized proforma. We collated data for 24 patients from 3 centers. Statistical comparisons were performed using Mann-Whitney test for continuous variables, Fisher exact test for categorical data, and log-rank test for survival data. Further methodology is included in this article's Online Repository at www.jacionline.org.
We found a higher prevalence of liver disease (33%) in patients with XHIM compared with most other studies: approximately 20% in data from a European registry 5 and a multinational study, 6 and only 6% in 2 US registries. 4, 7 A small case series from Newcastle described liver disease in 3 of 8 patients with XHIM (37.5%) and there is likely to be a notable overlap with our patient population from Newcastle. 8 Our study found that patients with XHIM without liver disease had normal liver biochemistry, normal imaging, and normal histology, where performed. However, patients with XHIM with liver disease had (1) statistically significant elevations in liver biochemistry excluding albumin (Table I; see Fig E1 in this article's Online Repository at www.jacionline.org); (2) abnormal liver imaging including splenomegaly, heterogeneous or cirrhotic appearing livers, and biliary dilatation or sclerosing cholangitis; and (iii) abnormal histology showing cholangiopathy/sclerosing cholangitis in 75% of those with liver disease, chronic hepatitis in 50%, and both features in 25% (see Table E2 in this article's Online Repository at www.jacionline.org).
Cryptosporidium and cytomegalovirus (CMV) infection have previously been associated with the development of cholangitis in patients with XHIM. 5, 9 In our case series, 38% of patients with liver disease tested positive for Cryptosporidium, and the prevalence was 3 times higher than in patients without liver disease (13%) ( Table I ). However, we did not find a statistically significant association between Cryptosporidium infection and the development of liver disease, or indeed, sclerosing cholangitis. CMV prevalence was not different between patients with XHIM with or without liver disease (Table I) .
Crude mortality was higher in the liver disease group (38%) compared with the group without liver disease (6%). Although the average age of patients was higher in the liver disease group (39.1 years vs 18.4 years), the standardized mortality ratio of 94 in those with liver disease versus 16 in those without supports this conclusion by correcting for this potential confounding factor (see Table E3 in this article's Online Repository at www.jacionline.org).
Kaplan-Meier log-rank analysis shows decreased survival in patients with XHIM with liver disease, regardless of whether time 0 is plotted as birth (hazard ratio 4.5; P > .05) or as date of diagnosis of XHIM (hazard ratio, 6.9; P 5 .05) (Fig 1, A and B, respectively). Our data reflect the survival curves in a highly powered recent study. 6 ALT, Alanine transferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; GvHD, graft versus host disease; max, maximum; min, minimum; PT, prothrombin time. *Range includes newborn to adult.
Hematopoietic stem cell transplant (HSCT) was performed in 89% of patients without liver disease (average age of HSCT, 3.1 years) compared with 50% in those with liver disease (average age of HSCT, 14.5 years). Early HSCT before age 10 years was performed in those without liver disease and survival was excellent. All patients with liver disease were transplanted as teenagers and liver disease at the time of HSCT conferred a poor prognosis, with the exception of a patient who was contemporaneously liver transplanted (see Fig 1, C, and discussion in this article's Online Repository at www.jacionline.org).
A previous study has described the survival benefit in XHIM all-comers, 10 but we show that those with early HSCT do not develop liver disease despite an average follow-up of 11 years, and this confers a notable survival benefit (P 5 .0022). Multivariate analysis supports this conclusion and further discussion can be found in this article's Online Repository at www.jacionline.org.
To date, this is the most detailed study of liver disease in XHIM. We conclude that liver disease in patients with XHIM is a lateroccurring diagnosis, characterized histologically by sclerosing cholangitis and chronic hepatitis, which has a poorer outcome and may be preventable through early HSCT. Patients with XHIM should undergo annual monitoring of liver function tests, including gamma-glutamyl transpeptidase and clotting, liver imaging (especially in those without HSCT), and exclusion of pathogens such as Cryptosporidium and CMV via PCR even if patients are asymptomatic. The presence of liver disease confers a poor prognosis in these patients and we strongly advocate specialist hepatology input in their management. Early diagnosis is key and a multidisciplinary approach regarding HSCT and liver transplantation should be sought.
We acknowledge authors whose work could not be cited in the main article because of reference limitations. We thank the reviewers and editors for their input on optimizing the manuscript. B cells rely on a broad receptor repertoire to provide protection against a wide range of pathogens. This is in part achieved through V(D)J recombination, which, by assembling various combinations of variable (V), diversity (D), and joining (J) genes, creates different IgV regions. 1 The recombination processes is initiated by recombination-activating gene (RAG) 1/RAG2 enzymes and requires a functional nonhomologous end-joining (NHEJ) machinery. B cells can further diversify their IgV regions through somatic hypermutation (SHM) to improve affinity between the antibody and antigen and switch the isotype of antibody produced by class-switch recombination (CSR). Both processes are initiated by activation-induced cytidine deaminase (AID) and rely on transcription and a number of DNA repair mechanisms.
Cornelia de Lange syndrome (CdLS) is a rare multisystem developmental disorder characterized by typical facial features, intellectual disability, and multiple congenital anomalies. 2 Most patients with CdLS have deleterious mutations in the gene encoding the cohesin loader Nipped-B-like (NIPBL), but mutations in the other cohesin-related genes SMC1A, SMC3, PDS5B, RAD21, or HDAC8 have also been identified in selected patients. Cohesin has been implicated in regulation of sister chromatid cohesion, transcription, long-range gene interactions, and DNA repair. 3 Aberrant CSR patterns have been observed in B cells from patients with NIPBL mutations. 4 Here we further investigated whether V(D)J recombination or SHM is affected in patients with CdLS. In chromosome-integrated V(D)J reporter assays, a reduced substrate recombination efficiency was observed in NIPBL knockdown human fibroblast or murine pro-B cells (see Fig E1 and the Methods section in this article's Online Repository at www.jacionline.org).
We next analyzed the IGH repertoire in 5 patients with NIPBL mutations and 3 patients with SMC1A mutations with CdLS (see Table E1 in this article's Online Repository at www.jacionline.org). The overall diversity of the IGHV repertoire, which is estimated by either the proportion of sequences with a unique complementary determining region 3 (CDR3) divided by the total number of sequences or by cumulative 50% of the total CDR3s in the samples (diversity 50 [D50]), which is a measurement of the evenness of the distribution of B-cell clones, was significantly lower in patients with NIPBL or SMC1A mutations (Fig 1, A and B) . Thus the patients with CdLS had a reduced overall diversity of their IGHV regions, with an overrepresentation of large B-cell clones.
Furthermore, in patients with NIPBL mutations with the classical form of the disease and in patients with SMC1A mutations, the frequency of IGHV genes located in the most proximal one third of the IGH locus (about 250 kb) was increased (Fig 1, C , and see Fig E2 in this article's Online Repository at www.jacionline.org). The observed skewed pattern of VH genes in the patients is likely to be a result of B cell-intrinsic changes because only sequences resulting from unproductive rearrangement (successfully rearranged but out of reading frame or containing stop codons) were included in this analysis, and an influence of antigen selection can thus be excluded.
The overall mutation frequency in the unproductive and most commonly mutated IGHV genes was also reduced in the patients with CdLS, reaching statistical significance for the group with an NIPBL mutation (Fig 2, A) . The proportion of unmutated sequences was increased in the patients with NIPBL mutations, especially in those with the classical form of the disease (Fig 2,  A) . However, the pattern of base pair substitution in the V regions was largely normal in the patients (Fig 2, B) .
Our data suggest that the cohesion-associated proteins NIPBL and SMC1A are involved in regulation of V(D)J recombination in human B cells, possibly through regulation of locus contraction. Increased use of proximally located IghV genes has previously been observed in mice deficient in factors associated with locus contraction, such as Ikaros, Yin Yang 1, and Pax5, and the cohesin interaction partner CCCTC-binding factor has been suggested to regulate locus contraction and V(D)J recombination at the mouse Igh locus. [5] [6] [7] Another possible explanation of how NIPBL/SMC1A could affect V(D)J recombination could be a change in regulation of DNA repair. We have previously observed a correlation between heterozygous NIPBL loss-of-function mutations and increased sensitivity to g-radiation and a shift toward use of microhomology-based end-joining during CSR, suggesting that NIPBL regulates the NHEJ process. 4 However, the V(D)J coding junctions generated in vivo in patients with CdLS showed a normal repair pattern (see Table E2 in this article's Online Repository at www.jacionline.org). Furthermore, expression of a number of key V(D)J recombination factors was largely normal in NIPBL knockdown cells (see Fig E3, B, in this article's Online Repository at www.jacionline.org). Thus the core NHEJ machinery appears to be retained in patients with CdLS.
We also found a reduced frequency of mutations within the IGHV regions in patients with CdLS. NIPBL and SMC1A could both be involved in the SHM process through regulation of transcription or RNA polymerase pausing, which promotes formation of single-stranded DNA and AID targeting. In support of this notion, there was a reduced number of mutations observed in the RGYW motifs (containing the AID hotspot in the bottom strand) in NIPBL 1/2 and SMC1A 2 cells, suggesting an impaired mutagenesis of C residues on the bottom strand (Fig 2, C) . We have previously observed the opposite pattern in NBS1-deficient cells. 8 Thus the targeting of AID and/or linked repair seem to be asymmetric during SHM, and this can be regulated by a number of factors, including the cohesin-associated factors.
CdLS is not traditionally considered an immunodeficiency disorder, but these patients have an increased prevalence of severe infections. 9 Immunodeficiency, including mild B-cell lymphopenia, reduced switched memory B-cell numbers, and/or reduced serum immunoglobulin levels, has been observed in previous case reports 9 and in our own patients (see Table E3 in this article's Online Repository at www.jacionline.org). Complete knockout of NIPBL is incompatible with survival, and
METHODS
All UK centers submitting XHIM data to the UK Primary Immunodeficiency Network were asked to complete a proforma to standardize the data collection (details in Letter to the Editor). Three centers contributed data for 24 patients in total. Criteria for submission of patients included definitive genetic or mutational analysis confirming XHIM, functional analysis showing absent CD40L protein, probable diagnosis of XHIM based on X-linked inheritance, male sex, or clinical presentation diagnosed by participating clinicians.
The proforma data included the patient's age, sex, whether XHIM was a de novo CD40L deficiency or whether there was a family history of the condition, genetic/mutation/molecular analysis, diagnosis date of CD40L deficiency, immunoglobulin maximum and minimum levels, medical history, allergies, current medications, and values of alanine transaminase, gamma-glutamyl transpeptidase, alkaline phosphatase, bilirubin, albumin, and prothrombin time (PT). Data were collected regarding evidence of liver disease from histology or from imaging including ultrasound (US), computerized tomography (CT), magnetic resonance cholangiopancreatography (MRCP), and endoscopic retrograde cholangiopancreatography (ERCP). Information regarding formal hepatology review and HSCT was recorded. Questions were also asked about the presence of hepatotrophic viruses including CMVand the presence of Cryptosporidium and its management, with additional enquiry regarding symptoms of chronic diarrhea.
Data were analyzed in Graphpad Prism using methods described in the main article. P values of less than .05 were considered statistically significant. Multivariate analysis was performed in ClustVis (http://biit.cs.ut.ee/clustvis/).
RESULTS

Mutational analysis, immunological findings, and clinical phenotype
All 24 patients were males and about half had an X-linked pattern family history of XHIM. All had missing CD40L expression and 67% had genetics or mutational analysis performed (Table E1 ). There were no T-cell abnormalities in our patient cohort, in keeping with diagnostic guidelines. We documented minimum and maximum immunoglobulin levels, corresponding to preintravenous and postintravenous immunoglobulin therapy. Although there was a lack of association with IgA and IgG levels, patients with liver disease had statistically higher maximum IgM levels ( Table I) . The clinical phenotype of our patients was sinopulmonary disease in 83%, gastrointestinal disease in 54%, liver disease in 33%, hemaopoietic disorders in 33%, central nervous system disorders in 13%, and skin manifestations in 8% (Table E1) .
Liver biochemistry
Eight patients (33% of the XHIM cohort) demonstrated convincing biochemical liver disease with confirmatory radiological and histological evidence. One patient developed graft versus host disease after HSCT. This patient was not considered to have XHIM-related liver disease (see discussion below).
Patients with XHIM with liver disease had statistically significant elevations in alkaline phosphatase, gamma-glutamyl transpeptidase, alanine transaminase, bilirubin, and PT when compared with those without liver disease. However, there was no statistical difference in the albumin level (Fig E1) . Hepatotrophic viruses were routinely checked in clinical practice-hepatitis B and C were absent in the current cohort.
Liver imaging
Nine of the 16 patients without liver disease had abdominal imaging available, all of which were reported as normal (Table I ). All patients with liver disease showed imaging abnormalities on various modalities such as US, CT, MRCP, or ERCP. The most common abnormalities were splenomegaly, a heterogeneous or cirrhotic appearing liver, and biliary dilatation or sclerosing cholangitis. Typical findings for those with liver disease are listed in Table E2 .
Liver histology
All patients with abnormal liver biochemistry and radiology underwent liver biopsy. Histological cholangiopathy/sclerosing cholangitis was the most common liver abnormality, seen in 6 patients (75%), followed by chronic hepatitis in 4 patients (50%) or both features in 2 patients (25%). Granulomatous hepatitis was also observed in 1 patient (13%) who also had chronic hepatitis. There was no secondary cause of granuloma formation in this patient.
All patients with histological sclerosing cholangitis had a dilated biliary tree, cholangiopathy, or overt sclerosing cholangitis on their imaging. Histological chronic hepatitis could not be identified from imaging alone (Table E2 ). CD40L mutation pattern did not correlate with the development of liver disease.
Gastrointestinal infections
Chronic diarrhea was present in 50% of those without liver disease and 38% of those with liver disease (not statistically significant). Cryptosporidium infection was identified in 2 of 16 (13%) patients without liver disease and 3 of 8 (38%) patients with liver disease; this trend did not reach statistical significance (Table I) . Asymptomatic Cryptosporidium infection was present only in the liver disease group (25%). Cryptosporidum was diagnosed by microscopy in 5 patients with supplementary PCR testing in 2 patients.
CMV rates of 19% (3 of 16 patients) in the group without liver disease were not significantly different from 13% (1 of 8 patients) in the liver disease group (Table I ). All patients were tested by PCR. Diarrhea manifested in half of the affected patients.
DISCUSSION
Genetic analysis and clinical phenotype
There was no correlation between mutation type (deletion, frameshift, premature stop codon) or the CD40L domain affected, and the clinical phenotype, consistent with previous findings.
E1-E5
We noted that maximum IgM levels are higher in the liver disease group, but the clinical significance of this finding is unclear. It has previously been reported that IgM levels may increase with age, E5 and our findings may simply reflect an older cohort in the group with liver disease.
Role of liver imaging and histology
Patients with biopsy-proven liver disease had elevated liver function tests (except for albumin) and prolonged PT compared with those without liver disease (Table I and Fig E1) . All patients with liver disease had abnormal liver imaging in the form of US, MRCP, or ERCP (Table I and Table E2 ). Sclerosing cholangitis/ cholangiopathy was the most common presentation and could be predicted from the biliary dilatation seen on various imaging modalities (US, CT, MRCP, ERCP). Chronic hepatitis was not easily predicted from imaging (Table E2) .
We consider it of paramount importance that patients with XHIM are screened annually for liver disease with blood tests including liver function and clotting, with a low threshold for consideration of abdominal imaging if any abnormalities are detected. Hepatotrophic viruses should be excluded in all patients with abnormal liver function test results and we recommend early hepatology input to manage liver disease burden.
Detection of Cryptosporidium and CMV
Previous studies have suggested a role of persistent Cryptosporidium infection leading to biliary disease in this group of patients. E2,E5 Studies looking at CD40 agonist antibody use in CD40L deficiency have shown suppression of Cryptosporidium ooyst shedding into the stool with this therapy. E6 In a previous case series of 79 patients, it was demonstrated that in 5 patients with sclerosing cholangitis, 4 had Cryptosporidium infection, E7 whereas in a more recent study, Cryptosporidium was present in 25% of patients with XHIM with liver disease and 7% in the overall cohort. E1 In our case series, 38% of patients with liver disease tested positive for Cryptosporidium, and the prevalence was 3 times higher than in patients without liver disease (13%) ( Table I ). We could not find a statistically significant association between Cryptosporidium infection and the development of liver disease, or indeed, sclerosing cholangitis. Our methodological preference is to test for Cryptosporidium using PCR because previous studies have shown microscopy to be less sensitive and less specific than PCR analysis for Cryptosporidium infection. E8,E9 On the basis of our data showing that some patients had asymptomatic Cryptosporidium infection, we would also advocate testing for this pathogen in all immunodeficient patients because early treatment (eg, with nitazoxanide) may delay/prevent the development of cholangiopathy. E10 As we do in clinical practice, we recommend advising patients with XHIM to boil or filter tap water to reduce their risk of infection; there is limited data that rates of endemic Cryptosporidium transmission may be higher in immunocompromised individuals.
E11
In addition to cryptosporidiosis, CMV has been implicated in the pathogenesis of cholangiopathy in various immunodeficiencies including HIV infection E12 and XHIM. E2,E13 However, we found no significant difference in CMV prevalence between those with or without liver disease (Table I) .
Interestingly, the pathophysiology of CD40L deficiency and sclerosing cholangitis suggests a role for TNF-a. In mouse models, infection of CD40L-deficient mice with Cryptosporidium leads to chronic infection and cholangitis. E14,E15 Furthermore, CD40L knockout mice showed increased mRNA for Tnfrsf1a (TNF-a) and Tnfrsf1b (TNF-b). In addition, TNF-a production was seen in areas of inflammation of biliary epithelium on microscopy. E15 Triple knockout mice for CD40L/Tnfrsf1a/ Tnfrsf1b did not develop sclerosing cholangitis of biliary tree or gall bladder in the context of chronic Cryptosporidium infection. E15 Speculatively, therefore, TNF-a may be an important pathway in sclerosing cholangitis in patients with XHIM.
Hematopoietic stem cell transplantation
Several studies have reported that curative HSCT improves outcomes and survival of patients with XHIM and that younger age was optimal for the timing of transplantation because persistent infections and severe organ damage were frequently observed in older patients.
E16-E18
In our cohort, 75% of patients underwent HSCT, compared with other studies reporting rates ranging from 6% to 52%.
E1,E4,E7,E18 Eighty-nine percent (16 of 18) of patients in the group without liver disease were transplanted at an average age of 3.1 years, with a mean follow-up time of 11 years. One patient developed graft versus host disease in the liver post-HSCT, but underwent successful liver transplantation without further abnormalities in liver function. One patient died of severe graft versus host disease post-HSCT (Table E3) . No XHIM-related cholangiopathy or hepatitis has occurred in these patients despite an average of 11 years of follow-up post-HSCT. In comparison, only 50% (4 of 8) of patients in the liver disease group underwent HSCT at an average age of 14.5 years. Higher age and liver disease at HSCT conferred a poor prognosis (Fig 1, C) . The cause of death in 3 of these patients was liver failure (while awaiting liver transplantation), multiorgan failure secondary to hemophagocytic syndrome, and severe cryptosporidiosis. HSCT was performed alongside liver transplantation in 1 patient, who, of note, has not had liver disease recurrence despite a follow-up of more than 17 years. Two patients with liver disease who have not undergone HSCT have end-stage liver disease requiring liver transplantation and are currently undergoing assessment. In clinical practice, having treated XHIM-and other immunodeficiency-related liver diseases, we find that receiving liver transplantation without correction of the immunodeficiency confers an extremely poor prognosis (V. Azzu, W. J. H. Griffiths, unpublished data, 2017). Indeed in this study and elsewhere, we find that patients undergoing HSCT have far worse outcomes if they have liver disease that remains uncorrected (ie, without undergoing liver transplantation). Two previous reports support better outcomes in those undergoing both HSCT and liver transplantation. One case study indicates that HSCT shortly after liver transplantation prevented recurrence of liver disease in 1 patient. E19 Another study suggested that 2 patients who received liver transplantation after HSCT did well, compared with a patient receiving a liver transplant without HSCT, who went on to die. E1 We will therefore be approaching the transplant assessment of the aforementioned patients with a view to contemporaneous HCST because this likely confers a survival advantage.
There are several potential variables affecting survival in this data set (eg, HSCT timing and liver disease); early HSCT and no liver disease cluster closely to explain survival multivariate analysis (not shown). Although we cannot prove causality, these factors covary intimately, thereby hinting that early HSCT may confer a survival benefit by preventing liver disease onset.
The benefits of our study include detailed investigation of liver disease in a complex primary immunodeficiency as well as the inclusion of data from more than 1 center with a cross-sectional look at practice in the United Kingdom. Limitations include data gathered from a single country and less than full recruitment of all UK centers. GvHD, Graft versus host disease; SMR, standardized mortality ratio. *Cause of death in the group without liver disease: severe GvHD post-HSCT. Causes of death in the liver group: liver failure awaiting liver transplant, multiorgan failure secondary to hemophagocytic syndrome post-HSCT, and severe cryptosporidiosis.
